

Republic of the Philippines Department of Health FOOD AND DRUG ADMINISTRATION



FDA ADVISORY No. 2021-0202-A 1 2 MAR 2021,

TO:

THE GENERAL PUBLIC

SUBJECT:

Lifting the Advisory on the Notified Cosmetic Product "COLOURETTE COLOURGLAZE (DAYDREAM, BLANKET, SEROTONIN, SUNDOWN)" under FDA Advisory No. 2021-0202 "Public Health Warning Against the Purchase and Use of the following Unauthorized Cosmetic Products" Dated 01 February 2021

- 1. COLOURETTE COLOURGLAZE DAYDREAM
- 2. COLOURETTE COLOURGLAZE BLANKET
- 3. COLOURETTE COLOURGLAZE SEROTONIN
- 4. COLOURETTE COLOURGLAZE SUNDOWN

The Food and Drug Administration (FDA) informs the public that the Cosmetic product Colourette Colourglaze (Daydream, Blanket, Serotonin, Sundown) with Notification No. 1000007543048, has been notified by the Market Authorization Holder, NIV Della Beauty Innovations, Inc., in accordance with existing FDA rules and regulations.

Accordingly, the warning against the purchase and use of the subject product as mentioned in FDA Advisory No. 2021-0202 and its corresponding FDA Order is hereby lifted.

The public is advised to always check if a Cosmetic product is notified with the FDA by using the FDA Verification Portal feature accessible at https://verification.fda.gov.ph which may be used by typing in the name of the product before purchasing. For more information or inquiries, please email us at cchuhsrr-prsdd@fda.gov.ph. You may also call the Center for Cosmetics and Household/Urban Hazardous Substances Regulation and Research at telephone number (02) 8857-1900 loc.8113 or 8117.

To report the sale or distribution of any unnotified/unregistered health products, kindly email FDA via ereport@fda.gov.ph.

Furthermore, the issuance of this advisory shall not in any manner preclude this Office from issuing subsequent orders it may deem necessary and appropriate, should there be findings of any violation of the company to the existing laws, rules, and regulations.

Dissemination of this advisory to all concerned is hereby requested.

ROLANDO ENRIQUE D. DOMINGO, MD
Director General

DTN 20210115082533



